Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties (ECLIPSE)

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: December 4, 2008
Last updated: February 5, 2016
Last verified: February 2016

Primary objective:

- To assess the efficacy of eplivanserin 5mg/day in comparison to placebo after 6 weeks of treatment on sleep maintenance of insomniac patients, as measured by Polysomnography Wake Time After Sleep Onset (PSG-WASO) and Polysomnography Number of Awakenings (PSG-NAW).

Secondary objectives:

  • To evaluate the effects of eplivanserin 5mg/day as compared to placebo after 6 weeks of treatment on other sleep parameters measured by PSG recordings (Total Sleep Time - PSG-TST, Sleep Efficiency - PSG-SE, Latency to Persistent Sleep - PSG-LPS) and reported by patients (Wake Time After Sleep Onset - pr-WASO, Number of Awakenings - pr-NAW, Total Sleep Time - pr-TST, Quality of Sleep - QoS and Refreshing Quality of Sleep - RqoS).
  • To evaluate the effects of eplivanserin 5mg/day on sleep architecture compared to placebo.
  • To evaluate the effect of eplivanserin 5mg/day on daytime functioning using the Sleep Impact Scale (SIS), as compared with placebo after 6 weeks of treatment.
  • To evaluate patient's impression of treatment effects using the Patient's Global Impression questionnaire.
  • To evaluate the potential for next-day residual effects (using patient's morning questionnaire and psychometric tests) with eplivanserin 5mg/day as compared to placebo.
  • To evaluate the potential for rebound insomnia following abrupt discontinuation of eplivanserin 5mg/day in comparison with placebo.
  • To evaluate the effect of eplivanserin, compared to placebo, on the quality of life of patients with primary insomnia using the SF-36 Health Survey.
  • To evaluate the clinical safety and tolerability of eplivanserin 5mg/day compared to placebo.

Condition Intervention Phase
Primary Insomnia
Drug: Eplivanserin
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties: a 6-week, Randomized, Double-blind, Placebo-controlled, Polysomnography Study.

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Change from baseline of mean PSG-WASO on N41/N42 [ Time Frame: 6 weeks ]
  • Change from baseline of mean PSG-NAW on N41/N42 [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Other PSG sleep parameters: PSG-TST, PSG-SE (TST/Time in Bed), PSG-LPS [ Time Frame: 6 weeks ]
  • Patient-reported sleep parameters [ Time Frame: 6 weeks ]
  • Patient Global impression (PGI) [ Time Frame: 6 weeks ]
  • sleep architecture: percentage of time spent in each sleep stage (1, 2, 3-4/SWS, REM), shift to stage 1, shift to wake, stage 1 + WASO, [stages 3&4]/[stage 1 + WASO]). [ Time Frame: 6 weeks ]
  • Sleep Impact Scale (SIS) [ Time Frame: 6 weeks ]
  • SF-36 Health Survey [ Time Frame: 6 weeks ]

Enrollment: 637
Study Start Date: December 2008
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eplivanserin
Eplivanserin 5 mg/day
Drug: Eplivanserin
one 5 mg tablet once a day
Other Name: SR46349
Placebo Comparator: Placebo
Placebo of Eplivanserin 5 mg/day
Drug: Placebo
Placebo of Eplivanserin one tablet once a day

Detailed Description:

Randomized, double-blind, placebo, controlled study with 2 parallel groups Duration of treatment : 6 weeks

Duration of observation: 9 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of primary insomnia based on DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revisions) criteria

Exclusion Criteria:

  • Inpatients.
  • Mean screening PSG-WASO for screening night 1+ screening night 2 < 45 mn, or screening night with PSG-WASO < 30 mn.
  • Mean screening PSG-TST for screening night 1 + screening night 2 ≥7 hours or ≤3hours.
  • Mean screening PSG-LPS for screening night 1+ screening night 2 > 30 mn.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00805350

United States, New Jersey
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States, 08807
Sanofi-Aventis Administrative Office
Wien, Austria
Sanofi-Aventis Administrative Office
Laval, Canada
Sanofi-Aventis Administrative Office
Paris, France
Sanofi-Aventis Administrative Office
Berlin, Germany
Sanofi-Aventis Administrative Office
Budapest, Hungary
Sanofi-Aventis Administrative Office
Warszawa, Poland
Sponsors and Collaborators
Study Director: ICD CSD Sanofi
  More Information

Responsible Party: Sanofi Identifier: NCT00805350     History of Changes
Other Study ID Numbers: EFC10844
2008-003791-22 ( EudraCT Number )
Study First Received: December 4, 2008
Last Updated: February 5, 2016

Keywords provided by Sanofi:
Sleep Maintenance

Additional relevant MeSH terms:
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
SR 46349B
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on May 22, 2017